Prostate cancer Treatment's heart risks under the microscope
NCT ID NCT05096338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 200 men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy) for at least 6 months. Researchers want to understand how this treatment affects the heart over time, and how factors like medical history, race, income, and access to healthcare play a role. Participants will have heart ultrasounds, blood tests, and answer questions about symptoms and activity for up to 5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOTOXICITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can better healthcare access save hearts after prison?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- A second look: MRI screening may spot hidden prostate cancers
- Could a simple health chat slash heart disease and cancer risk?